-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Rubik's Cube Info
On September 5, Hengrui issued an announcement that the company and Beijing Tianguangshi Biotechnology Co.
, Ltd.
signed a cooperation agreement
.
The two parties reached an agreement, and Tianguangshi Biotech granted Hengrui Pharmaceutical the exclusive commercialization rights for the third-generation anti-CD20 antibody MIL62 in the Greater China region (including Mainland China, Taiwan, Hong Kong, and Macau).
MIL62 is a glycosylated humanized type II anti-CD20 monoclonal antibody developed by Tianguangshi Biology.
It is the first and currently the only third-generation anti-CD20 developed by a domestic pharmaceutical company that has entered the phase III clinical trial in China.
Antibody
.
Compared with the first-generation anti-CD20 antibody rituximab, the unique binding epitope and antibody glycosylation modification of MIL62 show stronger ADCC and anti-tumor activity
According to the agreement reached between Hengrui Medicine and Tianguangshi Bio, Tianguangshi Biotech granted Hengrui Medicine the exclusive and exclusive commercialization rights for MIL62 in the Greater China region, and jointly carried out clinical research on the combined use of MIL62 and Hengrui Medicine-related products.
.
The two parties will set up a joint research and development committee, and the two parties will jointly be responsible for the implementation of the clinical trials of the MIL62 and Hengrui Pharmaceutical-related products jointly developed by the two parties in the licensed area, and the research and development costs will be borne by both parties
As of now, only one third-generation anti-CD20 monoclonal antibody has been approved for marketing in the world, which is obinutuzumab (developed by Roche, under the trade name Gazyva), which has been approved for marketing in China
.
According to the database of EvaluatePharma, global sales of obinutuzumab in 2020 are approximately US$724 million
